Sector News

PhRMA finally launches campaign to discuss drug costs

July 17, 2017
Life sciences

Probably one of the last things the pharma industry wants to talk about today is the cost of drugs. Or does it? Industry trade group PhRMA has launched new advertising meant to tackle the issue head-on.

The national campaign, “Let’s Talk About Cost,” is a specific print, radio, digital and social effort, but that moniker will also now serve as the branded umbrella for all of PhRMA’s cost and value communications that have been going on for years. That includes Share the Savings discussions around rebates and discounts, and the Value Collaborative effort to engage leaders on reform issues.

“We’ve been actively making sure that we are putting the cost and value of medicines in perspective for many years now. Too often though, so many of the conversations still focus on costs and spending from 2014, which we know was an anomaly year,” Holly Campbell, senior director of communications at PhRMA, said in an interview, referencing the year that saw the introduction of expensive hepatitis C cures. “Unfortunately, those are still the points most often used in conversations. We need to make sure the new facts and trends moving forward on medicine costs and spending are reflected.”

The initial print ad, which ran last week in The Wall Street Journal, was a series of four questions, including “Why am I paying more than my insurer for my medicine?” and “Who decides what I pay for my medicine?” The ad redirects readers to the custom website at phrma.org/letstalkaboutcost for the answers.

The other part of the cost effort is acknowledging the struggle some patients face to pay for medicines they need and help them to find answers, Campbell said. The campaign will also highlight the online resource Partnership for Prescription Assistance, a PhRMA kind of clearinghouse website where patients can get information about reduced price or free prescription medication programs through pharma companies and third-party providers.

The new cost savings advertising umbrella works in conjunction with PhRMA’s broader Go Boldly branding initiative to strengthen the pharma industry’s reputation. The body has spent millions on that science-focused effort, which it unveiled in January, but critics have questioned whether the industry could really salvage its battered reputation without even mentioning the controversial cost issue.

By Beth Snyder Bulik

Source: Fierce Pharma

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]